By 2030, it is anticipated that the France Radiotherapy Market will reach a value of $281 Mn from $190 Mn in 2022, growing at a CAGR of 5% during 2022-2030. The Radiotherapy Therapeutics Market in France is dominated by a few domestic players such as Orfit Industries, Median Technologies, and Dosisoft. The radiotherapy market in France is segmented into different types, technologies, procedures, applications, and end-users. The major risk factors associated with awareness of radiotherapy shortage of skilled staff, government initiatives, and reimbursement policy. The demand for French radiotherapy is increasing on account of the rise in cancer cases in the country.
By 2030, it is anticipated that the France Radiotherapy Market will reach a value of $281 Mn from $190 Mn in 2022, growing at a CAGR of 5% during 2022-30.
France is a developed country in Western Europe with various overseas territories and islands on other continents and in the Indian, Pacific, and Atlantic oceans. Cancer care accounted for around 12% of total health costs in France in 2019. In 2020, France had an age-standardized oncology incidence rate of 340 per 100,000 population. France has a larger cumulative risk of incidence than the rest of Europe, at 32.7%. When compared to other locations, this one has a reduced mortality risk of 11.2%. In total, about 3.9 Mn radiation sessions were performed in France, with around 990,000 performed in public health facilities. France’s government spent 12.2 % of its GDP on healthcare in 2020.
Market Growth Drivers Analysis
Radiotherapy is used to treat around two out of every three cancer patients in France, or nearly 190,000 people each year. Patients in France benefit from an efficient system of access to novel pharmaceuticals through the Temporary Use Authorization (TUA) system. Increasing government funding on several innovative cancer treatment options. These aspects could boost France's, Radiotherapy Market.
Market restraints
In France, there is a shortage of specialised human resources for radiation. There were just five diagnostic radiology and radiation specialists in the Île-de-France region. These factors may deter new entrants into the France Radiotherapy Market.
Key Players
March 2021: The Institut Curie and the Italian business SIT have signed the first joint research initiative in the field of "Flash" radiation. After months of hard labour, the two partners have created a high-performance, dependable, and operational experimental research platform (ElectronFlash). This revolutionary technology paves the path for clinical uses of Flash irradiation and opens up new avenues in cancer treatment.
In France, radiotherapy is regulated by various agencies and organizations, including the French National Authority for Health (Haute Autorité de Santé or HAS), the French Society of Radiation Oncology (SFRO), and the French Agency for Safety of Health Products (Agence nationale de sécurité du médicament et des produits de santé or ANSM). HAS is responsible for evaluating and approving radiotherapy techniques, protocols, and equipment to ensure that they are safe and effective. In terms of reimbursement, radiotherapy is covered by the French national health insurance system, which reimburses a portion of the cost of treatment.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Type (Revenue, USD Billion):
?By Technology (Revenue, USD Billion):
By Application (Revenue, USD Billion):
By End User (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
By 2030, it is anticipated that the France Radiotherapy market will reach a value of $281 Mn from $190 Mn in 2022, growing at a CAGR of 5% during 2022-2030.
In France, radiotherapy is regulated by various agencies and organizations, including the French National Authority for Health (Haute Autorité de Santé or HAS), the French Society of Radiation Oncology (SFRO), and the French Agency for Safety of Health Products (Agence nationale de sécurité du médicament et des produits de santé or ANSM).
The Radiotherapy Therapeutics Market in France is dominated by a few domestic players such as Orfit Industries, Median Technologies, and Dosisoft.